Different mechanisms for activation of gene transcription by interferons alpha and gamma. 1985

C R Faltynek, and S McCandless, and J Chebath, and C Baglioni

Treatment of HeLa cells with either recombinant interferon (rIFN) alpha 2 or gamma elevated the level of mRNA for 2',5'-oligo(A) synthetase and for a 56,000 Mr protein. Cycloheximide prevented the induction of these mRNAs when rIFN-gamma, but not rIFN-alpha 2, was the inducer. This suggested that these rIFNs activate gene transcription by different mechanisms. The level of induced mRNAs reached a maximum 8 or 12 hr, respectively, after addition of rIFN-alpha 2 or rIFN-gamma, and then slowly decreased. Inhibition of protein synthesis by cycloheximide 8 hr after the addition of rIFN-alpha 2 prevented the decline in mRNA for 2',5'-oligo(A) synthetase. Addition of an inhibitor of RNA synthesis or removal of IFN from the medium accelerated this decline. Although the IFN-alpha receptors were down-regulated in HeLa cells treated for 25 hr with rIFN-alpha 2, these cells responded to a second rIFN-alpha 2 treatment with a further increase in inducible mRNAs. These results suggest that the level of these mRNAs is regulated by two opposing processes. As long as IFN is present in the medium, it continues to activate transcription of inducible mRNAs. However, after 8-12 hr of treatment, an opposing process, which is inhibited by cycloheximide, causes a decline in the level of these mRNAs.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D005796 Genes A category of nucleic acid sequences that function as units of heredity and which code for the basic instructions for the development, reproduction, and maintenance of organisms. Cistron,Gene,Genetic Materials,Cistrons,Genetic Material,Material, Genetic,Materials, Genetic
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell

Related Publications

C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
November 1990, Nucleic acids research,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
January 1995, Gene expression,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
January 1988, Voprosy virusologii,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
August 1985, Infection and immunity,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
August 1983, Infection and immunity,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
January 1997, In vivo (Athens, Greece),
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
March 1993, Virology,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
May 1993, Nucleic acids research,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
October 1989, Genes & development,
C R Faltynek, and S McCandless, and J Chebath, and C Baglioni
January 1993, Annales de medecine interne,
Copied contents to your clipboard!